Helius Medical Technologies | StockChase
9
Helius Medical Technologies (HSM-T)

Last Price Recorded: $3.0500 on 2017-11-16

ON STOCKCHASE SINCE Apr 2016

Healthcare

Helius Medical Technologies



ABOUT CHARTS : These are thumbnail sketches of the stock prices, from the time of the opinions. The charts are not detailed, and are meant only to give an oveview (note the number of datapoints). The charts show one month of information or up to six months if you are a subscriber. Recent opinions will obviously have fewer datapoints then older opinions.


You are not seeing charts because you haven't logged in or haven't opted in

Date Signal Company Opinion Expert
2017-11-16
WATCH

HSM-T

$3.050

Helius Medical Technologies


They put out some numbers from their trial that an analyst said was a failure.  The control group showed a 75% result but the control group had a 60% result.  It is an electrical current so they had to give the control group some current otherwise they would know.  There is more data coming out and then in a year we will know.

Healthcare

Fabrice Taylor

Publisher

2017-10-05
COMMENT

HSM-T

$4.160

Helius Medical Technologies


A medical device that helps brain injury, as well as the potential to help with other diseases. He started recommending this at about $1.25, and it doubled in about a year, and he added more to his holdings. At this point, he has his original money out, but still owns a lot. Feels it has a lot of potential. It looks like FDA approval is a given and the data is coming out in a couple of weeks.

Healthcare

Fabrice Taylor

Publisher

2017-08-21
SPECULATIVE BUY

HSM-T

$2.810

Helius Medical Technologies


They make a device that is being tested to treat traumatic brain injury including a lot of soldiers in the US.  Results should be out in September.  Data is what gets people excited.  If it is good and early signs are good.  Then they go into FDA approval and the stock multiplies in price.  It is high risk, but he thinks you will see enthusiasm in September.  He is confident they will get FDA approval.  The military really needs this to happen for all their wounded soldiers. 

Healthcare

Fabrice Taylor

Publisher

CAUTIOUS
2017-05-30
PAST TOP PICK

HSM-T

$2.150

Helius Medical Technologies


(A Top Pick April 27/16. Up 31%.) Still very bullish on this. Makes a medical device that can help with traumatic brain injuries, along with other things. They are close to sending in data to FDA on a traumatic brain injury study. Thinks the stock is going to start to move as we get closer to that date. It looks like this could be an “over-the-counter” product for consumers.

Healthcare

Fabrice Taylor

Publisher

2017-05-30
TOP PICK

HSM-T

$2.150

Helius Medical Technologies


He thinks there is going to be a run up, because often times in Biotech’s you get a run into the news, so he thinks it will do well as we get closer to the big announcements, regardless of what the outcome is. The downside has been mitigated by the fact that it could be a consumer business. (Analysts’ price target is $2.34.)

Healthcare

Fabrice Taylor

Publisher

2017-02-16
SPECULATIVE BUY

HSM-T

$2.150

Helius Medical Technologies


The odds for shareholders have improved.  They are in FDA trials.  They are speculative and make no money.  He likens it to a lottery ticket or better, to a raffle ticket as the odds are better. 

Healthcare

Fabrice Taylor

Publisher

SELECTIVE
2016-12-02
SPECULATIVE BUY

HSM-T

$1.890

Helius Medical Technologies


A biotech company. Speculative because they don’t have any revenues yet. They are testing out a device called The Pons, which has been shown to improve a recovery rate in people that have traumatic brain injuries and illnesses like MS. In FDA trials right now. What makes it interesting is that it is in an unmet need.

Healthcare

Fabrice Taylor

Publisher

2016-09-09
SPECULATIVE BUY

HSM-T

$1.250

Helius Medical Technologies


Has a device that seems to be able to help people recover from MS, brain damage, etc., in conjunction with physiotherapy. They are in FDA trials right now. The real question is efficacy. What is interesting is that it is aimed at what is called an unmet need, i.e., there is nothing out there to treat people with traumatic brain injury. Very speculative. If they fail, the stock will get crushed, but if they succeed, the stock will go up a lot.

Healthcare

Fabrice Taylor

Publisher

2016-04-27
TOP PICK

HSM-T

$1.580

Helius Medical Technologies


Makes a medical device called the PONS, which appears to dramatically improve the results of therapy for people with brain injuries. They are in an FDA 3rd round right now. Results will probably be out in Q3. If results are positive, the stock will multiply, if not the stock is going to get crushed.

Healthcare

Fabrice Taylor

Publisher

Showing 1 to 9 of 9 entries

No Comments.


You must be logged in to comment.